GlycoMimetics, Inc. (NASDAQ:GLYC) Short Interest Update

GlycoMimetics, Inc. (NASDAQ:GLYC) was the target of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,870,000 shares, a growth of 30.5% from the February 13th total of 2,200,000 shares. Currently, 4.9% of the shares of the company are short sold. Based on an average daily volume of 1,460,000 shares, the short-interest ratio is currently 2.0 days.

GlycoMimetics Price Performance

GLYC stock opened at $0.27 on Wednesday. GlycoMimetics has a twelve month low of $0.14 and a twelve month high of $3.18. The business’s 50-day simple moving average is $0.27 and its 200 day simple moving average is $0.26.

GlycoMimetics (NASDAQ:GLYC) last released its earnings results on Thursday, February 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. As a group, equities research analysts expect that GlycoMimetics will post -0.08 EPS for the current fiscal year.

Institutional Investors Weigh In On GlycoMimetics

Institutional investors have recently added to or reduced their stakes in the company. Caxton Corp acquired a new stake in GlycoMimetics during the fourth quarter valued at approximately $51,000. ADAR1 Capital Management LLC boosted its holdings in GlycoMimetics by 626.1% during the fourth quarter. ADAR1 Capital Management LLC now owns 331,827 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 286,127 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in GlycoMimetics during the fourth quarter valued at approximately $106,000. Wellington Management Group LLP acquired a new stake in GlycoMimetics during the fourth quarter valued at approximately $352,000. Finally, VR Adviser LLC acquired a new stake in GlycoMimetics during the fourth quarter valued at approximately $747,000. 75.19% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on GlycoMimetics in a research note on Friday, March 14th. They issued a “sell” rating on the stock.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.